Chemotherapy for hormone refractory prostate cancer

Urologic Clinics of North America

Volumn 26, Issue 2, 1999, Pages 323-331

  Smith, D C ^a  

^a 7 302 CCGC 0946   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAMPTOTHECIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; HELICASE; LEDOXANTRONE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; SATRAPLATIN; SURAMIN;

BONE MARROW SUPPRESSION; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032912713     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70072-0     Document Type: Article

References (64)

1. R.J. Amato J. Ellerhorst C. Bui Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate Urol Oncol 1 1995 168
2. F.L. Abell J.D. Wilkes L. Divers Oral cyclophosphamide (CTX) for hormone refractory prostate cancer (HRPC) Proc Am Soc Clin Oncol 14 1995 243
3. R. Benson B. Hartley-Asp Mechanisms of action and clinical uses of estramustine Cancer Invest 8 1990 375
4. B. Blumenstein E.D. Crawford J.H. Saiers Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study J Urol 150 1993 411
5. J. Carles M. Domenech A. Gelabert-Mas Phase II study of estramustine and vinorelbine in hormone refractory prostate carcinoma patients Acta Oncol 37 1998 187
6. M. Colleoni C. Graiff G. Vicario Phase II study of estramustine, oral etoposide, and vinorelbine in hormone refractory prostate cancer Am J Clin Oncol 20 1997 383
7. G. Cruciani Phase II oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate: Instituto Oncologico Romagnolo, Gruppo Onco-Urologico Proc Am Soc Clin Oncol 17 1998 329a
8. M.A. Dimopoulos C. Panopoulos C. Bamia Oral estramustine and oral etoposide for hormone refractory prostate cancer Urology 50 1997 754
9. A.J. Dowling T. Panzarella I.F. Tannock Relationship between changes in serum prostatic specific antigen (PSA) and palliative response following treatment of symptomatic hormone refractory prostate cancer (HRPC) Proc Am Soc Clin Oncol 17 1998 1248a
10. M.A. Eisenberger R. Simon P.J. O'Dwyer A re-evaluation of nonhormonal cytotoxic chemotherapy in treatment of prostatic carcinoma J Clin Oncol 3 1985 827
11. M.A. Eisenberger L.M. Reyno D.I. Jodrell Suramin: An active drug for prostate cancer. Interim observations in a phase I trial J Natl Cancer Inst 85 1993 611
12. Ellerhorst J.S. Tu S.-M. R.J. Amato Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer Clin Cancer Res 3 1997 2371
13. S.J. Frank A. Amsterdam W.K. Kelly Platinum-based chemotherapy for patients (pts) with poorly differentiated hormone refractory prostate cancers (HRPC): Response and pathologic correlations Proc Am Soc Clin Oncol 14 1995 A601
14. B. Hartley-Asp E. Kruse Nuclear protein matrix as a target for estramustine-induced cell death Prostate 9 1986 387
15. G.R. Hudes R. Greenberg R.L. Krigel Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer J Clin Oncol 10 1992 1754
16. G.R. Hudes R. Kosierowski R. Greenberg Phase II study of topotecan in metastatic hormone refractory prostate cancer Invest New Drugs 13 1995 235
17. G.R. Hudes F. Nathan C. Khater Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer J Clin Oncol 15 1997 3156
18. G. Hudes B. Roth P. Loehrer Phase III trial of vinblastine versus vinblastine plus estramustine phosphate for metastatic hormone refractory prostate cancer (HRPC) [abstract] Proc Am Soc Clin Oncol 16 1997 A1127
19. M.H. Hussain K.J. Pienta B.G. Redman Oral etoposide in the treatment of hormone-refractory prostate cancer Cancer 74 1994 100
20. P.W. Kantoff M. Conaway E. Winer Hydrocortisone with or without mitoxantrone in HRPC: Preliminary results from a prospective randomized trial or the CALGB Proc Am Soc Clin Oncol 15 1996 2013
21. W.K. Kelly T. Curley C. Leibretz Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer J Clin Oncol 13 1995 2208
22. W.K. Kelly H.I. Scher M. Mazumdar Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer J Clin Oncol 13 1995 2214
23. R. LaRocca Use of suramin in treatment of prostate carcinoma refractory to conventional hormonal manipulation Urol Clin North Am 18 1991 123
24. J.A. Laurie R.G. Hahn T.M. Therneau Chemotherapy for hormonally refractory advanced prostate carcinoma: A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil Cancer 69 1992 1440
25. C.J. Logothetis M.L. Samuels von Eschenbach A.C. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer J Clin Oncol 1 1983 368
26. L. Lun P.M. Sun C.M. Trubey Helicase blockade by CI-958, a drug for prostate cancer [abstract] Proc Am Assoc Cancer Res 38 1997 A2068
27. C. Maulard-Durdux B. Dufour C. Hennequin Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone refractory prostate carcinoma patients Cancer 77 1996 1144
28. M.J. Moore D. Osoba K. Murphy Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer J Clin Oncol 12 1994 689
29. C.E. Myers M.R. Cooper C. Stein Suramin: A novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer J Clin Oncol 10 1992 881
30. H. Naik J. Lehr A. Akhtar Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats Anticancer Res 14 1994 2681
31. R.B. Natale S. Zarefsky Phase I/II trial of estramustine with Taxotere (T) or Vinorelbine (V) in patients (pts) with metastatic hormone refractory prostate cancer Proc Am Soc Clin Oncol 17 1998 338a
32. W.G. Nelson L.F. Liu D.S. Coffey Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells Nature 322 1986 187
33. D. Peereboom L. Wood C. Connell Phase II trial of oral platinum (JM-216) in hormone refractory prostate cancer (HRPC) Proc Am Soc Clin Oncol 17 1998 314a
34. D.P. Petrylak G. Shelton T. Judge Phase I trial of docetaxel (D) + estramustine (E) in androgen-insensitive prostate cancer (AIP) [abstract] Proc Am Soc Clin Oncol 16 1997 A1103
35. K.J. Pienta D.S. Coffey A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome J Cell Sci Suppl 1 1984 123
36. K.J. Pienta J.E. Lehr Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix J Urol 149 1993 1622
37. K.J. Pienta H. Naik J.E. Lehr Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo Urology 48 1996 164
38. K.J. Pienta B.G. Redman R. Bandekar A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer Urology 50 1997 401 discussion, 406
39. K.J. Pienta B. Redman M. Hussain Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate [see comments] J Clin Oncol 12 1994 2005
40. D. Raghavan G. Coorey M. Rosen Management of hormone-resistant prostate cancer: An Australian trial Semin Oncol 23 1996 20
41. D. Raghavan K. Cox B.S. Pearson Oral cyclophosphamide for the management of hormone refractory prostate cancer Br J Urol 72 1993 625
42. T.P. Rearden E.J. Small F. Valone Phase II study of mitoxantrone for hormone refractory metastatic prostate cancer [abstract] Proc Am Soc Clin Oncol 11 1992 A688
43. D. Reese H. Burris A. Belledgrun A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer (HRPC) [abstract] Proc Am Soc Clin Oncol 15 1996 A673
44. L.M. Reyno M.J. Egorin M.A. Eisenberger Development and validation of a pharmacokinetically based fixed dosing scheme for suramin J Clin Oncol 13 1995 2187
45. M.R. Robinson B. Richards D. Newling Weekly low-dose Adriamycin in advanced disseminated carcinoma of the prostate: A palliative approach Monogr Ser Eur Organ Res Treat Cancer 13 1984 187
46. B.J. Roth B.Y. Yeap G. Wilding Taxol in advanced, hormone-refractory carcinoma of the prostate: A phase II trial of the Eastern Cooperative Oncology Group Cancer 72 1993 2457
47. S. Saxman R. Ansari R. Drasga Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone refractory prostatic cancer: A Hoosier Oncology Group study Cancer 70 1991 2488
48. H. Scher A. Yagoda R.C. Watson Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma J Urol 131 1984 1099
49. J.D. Schmidt W.W. Scott R. Gibbons Chemotherapy Programs of the National Prostatic Cancer Project (NPCP) Cancer 45 1980 1937
50. W.W. Scott D.E. Johnson J.E. Schmidt Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: Results of first national randomized study J Urol 114 1975 909
51. A.D. Seidman H.I. Scher D. Petrylak Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer J Urol 147 1992 931
52. A. Sella R. Kilbourn R. Amato Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer J Clin Oncol 12 1994 683
53. E.J. Small M.E. Marshall L. Reyno Superiority of suramin + hydrocortisone (S + H) over placebo + hydrocortisone (P + H): Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer (HRPC) Proc Am Soc Clin Oncol 17 1998 308a
54. E.J. Small S. Srinivas B. Egan Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer J Clin Oncol 14 1996 1617
55. D.C. Smith N.J. Vogelzang H.L. Goldberg High-dose cyclophosphamide (Ctx) with granulocyte-macrophage-colony stimulating factor (Gm-CSF) in hormone-refractory prostatic carcinoma [abstract] Proc Am Soc Clin Oncol 11 1992 A666
56. L.A. Speicher L. Barone K.D. Tew Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines Cancer Res 52 1992 4433
57. I.F. Tannock Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3 1985 1013
58. I.F. Tannock D. Osoba M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points [see comments] J Clin Oncol 14 1996 1756
59. K.D. Tew M.E. Stearns Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine Urol Res 15 1987 155
60. F.M. Torti D. Aston B.L. Lum Weekly doxorubicin in endocrine-refractory carcinoma of the prostate J Clin Oncol 1 1983 477
61. D.L. Trump C.L. Loprinzi Phase II trial of etoposide in advanced prostate cancer Cancer Treatment Reports 68 1984 1195
62. D.L. Trump F.S. Freiha P.V. Woolley CI-958 phase 2 study in hormone refractory prostate cancer [abstract] Proc Am Soc Clin Oncol 15 1996 A648
63. B. Vogelstein D.M. Pardoll D.S. Coffey Supercoiled loops and eucaryotic DNA replication Cell 22 1980 79
64. von Roemeling R. H.A. Fisher J. Horton Daily oral cyclophosphamide is effective in hormone-refractory prostate cancer: A PH-I/II pilot study [abstract] Proc Am Soc Clin Oncol 11 1992 665A